Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 20/20 | 0.58 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25816019 | 1.00 | GLP1R (0.58) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL22062475 | 0.95 | GLP1R (0.57) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL24186661 | 0.91 | GLP1R (0.66) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL25816395 | 0.90 | GLP1R (0.55) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL25816445 | 0.90 | GLP1R (0.55) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL25821255 | 0.90 | GLP1R (0.55) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL23516172 | 0.89 | GLP1R (0.56) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL25816238 | 0.89 | GLP1R (0.48) | GLP1R | |
| SCHEMBL26364299 | 0.86 | GLP1R (0.52) | GLP1RCYP2C8KCNH2HTR1AHTR2A | |
| SCHEMBL30680710 | 0.86 | GLP1R (0.57) | GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322756-A1 | FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | GLP1R, GIPR, VIP | GLP1R 1/4885CYP2C8 145/4885KCNH2 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.